Alliance Revenue

9 Months Ended

Sep. 30, 2019

Note 8. Alliance Revenue

Alliance revenue for the three and nine months ended September 30, 2019 and 2018 represents revenue from contracts with customers accounted for in accordance with ASC Topic 606. For the three and nine months ended September 30, 2019 and 2018, Alliance revenue in the accompanying statements of operations and comprehensive loss is comprised of the following:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2019		2018		2019		2018
Out-license arrangement (1)	$	—	$	—	$	1,447	$	—
GSK collaboration (2)		—		141		—		424
Vivelix collaboration (3)		—		—		—		56
Other (4)		—		4		1		83
Total Alliance revenue	$	—	$	145	$	1,448	$	563

(1)

Revenue recognized in connection with the Licensee Agreement, as more fully described in Note 9.

(2)

Revenue recognized in connection with the GSK Agreement, as more fully described in Note 9.

(3)

Revenue recognized in connection with the Vivelix Agreement, as more fully described in Note 9.

(4)

For all periods presented, revenue recognized relates to collaborations which are not material to the Company’s current operations nor expected to be material in the future, including reimbursements by licensees of costs associated with patent maintenance.